Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison.
Naveen Pemmaraju, Alessandro Lucchesi, Stephen T Oh et al.
✦ AI-curated · Sources linked
In 30 seconds
This study conducted a matching-adjusted indirect comparison of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis. The analysis included data from Phase 3 randomized controlled trials, revealing trends favoring pacritinib in achieving symptom reduction, spleen volume reduction, and red blood cell transfusion independence, with an overall survival hazard ratio of 0.35 (95% CI 0.12, 1.05).
Key findings
- Pacritinib showed a trend towards greater TSS-50 achievement with an odds ratio of 1.75 (95% CI 0.60, 5.09).
- For spleen volume reduction, pacritinib had an odds ratio of 1.40 (95% CI 0.32, 6.04).
- Red blood cell transfusion independence was favored for pacritinib with an odds ratio of 1.19 (95% CI 0.36, 3.97).
- Overall survival favored pacritinib with a hazard ratio of 0.35 (95% CI 0.12, 1.05).
Why it matters
Understanding the comparative efficacy of treatments for thrombocytopenic myelofibrosis is crucial, as this condition significantly impacts patient morbidity and survival. Insights from this study may inform treatment decisions in clinical practice.